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ABSTRACT
The Notch1 and Notch4 signaling pathways regulate endothelial cell homeostasis. 
Inflammatory cytokines induce the expression of endothelial adhesion molecules, 
including VCAM1, partly by downregulating Notch4 signaling. We investigated the 
role of endothelial Notch1 in this IL-1β-mediated process. Brief treatment with 
IL-1β upregulated endothelial VCAM1 and Notch ligand Jagged1. IL-1β decreased 
Notch1 mRNA levels, but levels of the active Notch1ICD protein remained constant. 
IL-1β-mediated VCAM1 induction was downregulated in endothelial cells subjected 
to pretreatment with a pharmacological inhibitor of the γ-secretase, which activates 
Notch receptors, producing NotchICD. It was also downregulated in cells in which 
Notch1 and/or Jagged1 were silenced. 
Conversely, the forced expression of Notch1ICD in naïve endothelial cells 
upregulated VCAM1 per se and amplified IL-1β-mediated VCAM1 induction. Jagged1 
levels increased and Notch4 signaling was downregulated in parallel. Finally, 
Notch1ICD and Jagged1 expression was upregulated in the endothelium of the liver 
in a model of chronic liver inflammation. 
In conclusion, we describe here a cell-autonomous, pro-inflammatory endothelial 
Notch1-Jagged1 circuit (i) triggering the expression of VCAM1 even in the absence of 
inflammatory cytokines and (ii) enhancing the effects of IL-1β. Thus, IL-1β regulates 
Notch1 and Notch4 activity in opposite directions, consistent with a selective targeting 
of Notch1 in inflamed endothelium.
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INTRODUCTION
Notch signaling is an evolutionarily conserved 
pathway that modulates cell fate decisions through 
local cell-cell interactions [1]. In mammals, four type I 
transmembrane receptors, Notch1-4, and 5 Delta-Serrate 
ligands, Delta-like1 (Dll1), Dll3- 4 and Jagged1-2, have 
been identified [1, 2]. Notch activation mostly occurs when 
cell-surface ligands bind to Notch receptors on adjacent 
cells, triggering two consecutive proteolytic cleavages 
of the receptor, the second of which is mediated by the 
γ-secretase complex. The active protein, the cleaved Notch 
intracellular domain (NotchICD), relocates to the nucleus, 
where it interacts with the DNA-binding protein RBP-
Jk, activating a transcriptional complex known as CSL 
(for CBF1/Su(H)/Lag1) and containing mastermind-like 
(MAML) 1-3. The CSL-NotchICD complex then recruits 
co-activators, to induce the expression of canonical 
Notch target genes [3]. These genes include members 
of the Hes (Hairy and enhancer of split) and HRT/Hey 
(Hairy-related transcription) gene families encoding 
bHLH transcriptional regulators acting as repressors [3]. 
Non-canonical Notch signaling, involving the activation 
of NF-κB signaling and other pathways, has been 
described in several systems [4, 5]. All Notch paralogs 
can signal through similar pathways, but paralog-specific 
downstream effects have also been described [6-12]. 
The expression and activation of Notch signaling 
components are strictly tissue- and context-specific [13], 
complicating the situation even further. In the vascular 
bed, in addition to Dll1, Dll4, Jagged1 and Jagged2, 
endothelial cells also express both Notch1 and Notch4. 
The presence of Notch1has been reported in several other 
tissues, but Notch4 is present almost exclusively in the 
endothelium [14-21]. 
During the postnatal period, Notch signaling 
regulates a plethora of functions, including a number of 
inflammatory processes in different types of tissue [22-
29]. 
Inflammation triggers the upregulation of vascular 
cell adhesion molecule 1 (VCAM1) and E-selectin 
expression in endothelial cells. These two adhesion 
molecules promote the accumulation of leukocytes and 
their adhesion to blood vessel walls. This phenomenon 
is mediated by inflammatory cytokines, such as TNFα 
and IL-1β, through the activation of NF-kB and 
downregulation of Notch4 signaling [26]. Accordingly, 
decreases in the expression of Notch4 and/or its target 
gene, Hes1, are sufficient to trigger endothelial VCAM1 
expression, even in the absence of inflammatory cues [26]. 
TNFα and IL-1β have recently been shown to increase 
expression of the Notch2 receptor in endothelial cells, 
inducing apoptosis [28, 30]. These findings suggest that 
Notch receptors may have paralog-specific effects in 
inflamed endothelium. 
The role of Notch1 in the endothelial compartment 
during inflammation remains unclear. We show here, in 
different types of endothelial cells, that Notch1: i) induces 
the expression of adhesion molecules, such as VCAM1, 
even in the absence of inflammatory cytokines, and ii) 
potentiates IL-1β-dependent VCAM1 upregulation, 
presumably through Jagged1 overexpression and with a 
mechanism involving the NF-kB pathway. These findings 
provide evidence for a novel cell-autonomous pro-
inflammatory Jagged1-Notch1 pathway in endothelial 
cells, different from and acting in the opposite direction to 
the anti-inflammatory Notch4 signaling pathway occurring 
in the same cellular context.
RESULTS
IL-1β modulates Notch pathway components in 
endothelial cells
We analyzed the role of endothelial Notch1 in 
early inflammation, by treating human aortic endothelial 
cells (HAECs) with 10 ng/ml IL-1β for 6 h [31]. IL-
1β downregulated the levels of transcripts for the 
Notch ligands Jagged2, Dll1 and Dll4 and markedly 
upregulated those of the Jagged1 transcript (Figure 1A). 
As previously reported [26, 28], the levels of Notch1 and 
Notch4 transcripts decreased whereas those of the Notch2 
transcript increased (Figure 1B). Levels of Jagged1 protein 
and of the cleaved active form of Notch2 (Notch2ICD) 
increased markedly, whereas those of Notch4ICD 
decreased (Figure 1C). Interestingly, levels of the full-
length Notch1 protein were decreased by IL-1β treatment, 
whereas those of Notch1ICD remained similar to the levels 
in untreated cells (Figure 1C). These findings suggest that 
IL-1β activity underlies the activation of Notch1. 
As previously reported for TNFα, mRNA levels 
for the canonical Notch target gene Hes1 were strongly 
decreased, whereas those for Hey1 were markedly 
increased by IL-1β treatment (Figure 1B).
Substantial upregulation of Jagged1 levels by IL-1β 
was observed within one hour of treatment (Figure 1D, 
1E), consistent with previous reports [22, 27]. Similar 
effects of IL-1β were detected in human endothelial cells 
from different sources, including umbilical vein (HUVEC) 
and microvascular endothelial cells (HMVEC), and in 
cord blood endothelial progenitors (EPCs) (Supplementary 
Figure 1), suggesting that the effects of cytokines on the 
expression of Notch components are conserved between 
different types of endothelial cells. 
Oncotarget43218www.impactjournals.com/oncotarget
Figure 1: IL-1β modulates the expression of components of the Notch pathway in human aortic endothelial cells 
(HAECs). Confluent primary HAECs were treated with IL-1β (10 ng/ml) for 6 h or left untreated. A. mRNA levels (Sybr Green method, 
as reported in the Methods section) for Notch ligands were normalized with respect to β-actin and are expressed as the cDNA copy 
number (x103) (see Methods section). B. mRNA levels (Sybr Green method) for the Notch receptors Notch1, Notch2, Notch4 and for 
the Notch target genes Hes1 and Hey1 were normalized with respect to β-actin and are expressed as the cDNA copy number (x103) (see 
Methods section). A. and B.: Mean±SD. C. Representative western blot showing levels of Jagged1, full-length Notch1 (FL) and the Notch1 
intracellular domain (Notch1ICD) (left), Notch2ICD and Notch4ICD (right) in HAECs treated for 6 h with IL-1β or left untreated. β-Actin 
is the loading control. D. mRNA levels for Jagged1 in HAECs treated with IL-1β or left untreated for the reported times, quantified by the 
2(-∆∆Ct) method (see Methods section) after normalization with respect to β-actin, expressed as a fold-change with respect to untreated sample 
at 0.5 h (100 arbitrary units). Mean±SEM. E. Representative western blot showing levels of Jagged1 in HAECs treated with IL-1β for the 
reported times. β-actin is the loading control. All experiments were performed in duplicate and repeated independently at least 3 times. *P 
< 0.05, **P < 0.01, ***P < 0.001, t-test.
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Pharmacological inhibition of Notch signaling 
impairs IL-1β-induced VCAM1 expression in 
endothelial cells
We then investigated the role of Notch signaling 
in the IL-1β-dependent endothelial “activated” 
phenotype characterized by upregulation of the adhesion 
molecules VCAM1, ICAM1 and E-selectin [32]. We 
blocked the activation of Notch receptors in HAECs 
with the γ-secretase inhibitor DAPT (N-[N-(3,5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl 
ester), which prevents the activation/cleavage of Notch 
receptors in a non-selective manner. HAECs treated with 
5 µM DAPT for 16 h and then cotreated with DAPT and 
IL-1β for a further 6 h displayed a lower level of VCAM1 
upregulation than cells treated with IL-1β alone (Figure 
2A). With such pretreatment, DAPT downregulated the 
Notch targets Hey1 and Hes1, confirming the inhibition 
of canonical Notch activity (Figure 2B). In the absence of 
IL-1β, DAPT had no effect on VCAM1 expression. These 
results suggest that the activation of one or more Notch 
receptors may contribute to the endothelial induction of 
VCAM1 in an inflammatory context. 
Figure 2: Pharmacological inhibition of Notch signaling impairs IL-1β-induced VCAM1 upregulation in human aortic 
endothelial cells (HAECs). Confluent HAECs were subjected to pretreatment for 16 h with either the γ-secretase inhibitor DAPT (5 
μM) or vehicle (DMSO), and were then treated for six hours with DAPT and IL-1β (10 ng/ml) or with DAPT alone and subjected to flow 
cytometry analysis. (A., left) A representative histogram shows overlays of VCAM1 expression analyzed by flow cytometry: Vehicle 
(gray solid curve), DAPT (dotted line), IL-1 β + Vehicle (gray line) and IL-1β + DAPT (black line). (A., right) The histogram depicts 
the quantification of VCAM1 expression in IL-1β-treated cells, expressed as a mean fluorescence intensity (MFI), in arbitrary values. 
Mean±SD. B. mRNA levels of Hey1 (left) and Hes1 (right) in cells 16 h after treatment with either DAPT (5 µM) or vehicle (DMSO) were 
quantified by the 2(-∆∆Ct) method (see Methods section) after normalization with respect to β-actin, and are expressed as a fold-change relative 
to vehicle-treated cells (100 arbitrary unit). Mean±SEM. All the experiments were performed in duplicate and repeated independently at 
least 3 times. *P < 0.05, **P < 0.01, ***P < 0.001, t-test.
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The silencing of Notch1 and/or Jagged1 
counteracts the IL-1β-dependent upregulation of 
adhesion molecule expression in endothelial cells
DAPT and other γ-secretase inhibitors are non-
selective inhibitors of Notch receptors. We therefore 
transfected HAECs with siRNAs targeting either Jagged1 
or Notch1, to determine the specific roles of these 
molecules in the IL-1β-induced upregulation of VCAM1. 
We used a non-targeting siRNA (Scramble siRNA) as 
a control. The depletion of either Jagged1 or Notch1 
resulted in lower levels of VCAM1 upregulation upon IL-
1β treatment than were observed with the Scramble siRNA 
(Figure 3A, 3C). Moreover, (i) Jagged1 siRNA decreased 
Notch1ICD levels (Figure 3B); (ii) Notch1 knockdown 
also prevented the IL-1β-dependent induction of Jagged1 
(Figure 3D). Thus, in this context, Jagged1 activated 
Notch1, which, in turn, enhanced IL-1β-mediated Jagged1 
overexpression.
Following the silencing of both Jagged1 and Notch1 
in HAECs treated with IL-1β: (i) VCAM1 upregulation 
was inhibited (Figure 3E, 3F and Supplementary Figure 
2A, 2B): (ii) the decrease in Notch4ICD and Hes1 
levels was prevented (Supplementary Figure 2B) and 
(iii) the upregulation of both ICAM1 and E-selectin 
reduced (Supplementary Figure 2C, 2D). Moreover, 
Jagged1/Notch1 codepletion decreased Hey1 mRNA 
levels, suggesting that Notch1 activation triggered Hey1 
expression either directly or indirectly in this context 
(Supplementary Figure 2E). These results support the 
hypothesis that Jagged1 and Notch1 participate in a 
mechanism sustaining the IL-1β-mediated induction of 
inflammatory adhesion molecules in endothelial cells. 
They also suggest that the persistence of Notch1ICD in 
IL-1β-treated endothelial cells may be required for the 
induction of Jagged1. 
Notch1ICD overexpression induces VCAM1 
upregulation in endothelial cells
We used a gain-of-function approach to determine 
whether Notch1 activation was sufficient to trigger 
VCAM1 expression in HAECs. We cotransfected these 
cells with a plasmid encoding the human Notch1ICD 
and a plasmid encoding green fluorescent protein (GFP). 
Cells cotransfected with an empty vector (EV) and a 
GFP vector were used as controls (see Supplementary 
Figure 3A for cotransfection efficiencies). Strikingly, 
in the absence of IL-1β, Notch1ICD overexpression 
alone led to higher VCAM1 levels in HAECs than in 
EV-transfected cells (Figure 4A, 4B and Supplementary 
Figure 3B). Notch1ICD further enhanced the stimulation 
of VCAM expression by IL-1β treatment, as shown by 
comparisons with EV-transfected cells (Figure 4A, 4B). 
Consistent with the results of knockdown experiments, 
Notch1ICD expression also increased Jagged1 levels in 
both the presence and absence of IL-1β (Figure 4B and 
Supplementary Figure 3B). Notch1ICD overexpression in 
HAECs also had an effect similar to that of IL-1β reported 
in previous studies by our group and others [26, 30]: it 
resulted in higher levels of Hey1 and Notch2 transcripts 
and lower levels of Notch4 and Hes1 transcripts than 
observed for EV-transfected cells (Supplementary Figure 
3C). 
DAPT pretreatment did not abolish Notch1ICD-
dependent VCAM1 overexpression in HUVECs infected 
with a retroviral vector encoding the mouse Notch1ICD 
(Notch1ICD*) previously validated by our group [33] 
(Supplementary Figure 4), suggesting that the observed 
effects were specific to Notch1.
Thus, in the absence of other activated Notch 
paralogs, Notch1ICD was able to mimic the effects of IL-
1β on endothelial VCAM1 expression. 
The effects of Notch1ICD overexpression 
on VCAM1 in endothelial cells are partly 
counteracted by the pharmacological inhibition 
of NF-kB
NF-kB activation has been implicated in the TNFα-
mediated induction of endothelial VCAM1 [26, 27, 34]. 
We investigated the contribution of NF-kB signaling to the 
induction of VCAM1 expression by Notch1, by subjecting 
Notch1ICD*-overexpressing HUVECs to pretreatment 
for 1 h with the NF-kB inhibitor BAY 117082 (BAY; 20 
µM) before IL-1β treatment. BAY pretreatment abolishes 
NF-kB phosphorylation and signaling by inhibiting IkB 
kinase (IKK) activity [35], thereby blocking inflammatory 
VCAM1 expression in endothelial cells [34]. As expected, 
BAY pretreatment completely prevented the increase in 
VCAM1 levels in empty vector-transfected (EV*) cells 
treated with IL-1β (Figure 5A, 5B). It also attenuated the 
derepression of VCAM1 by Notch1ICD* in HUVECs in 
the absence of IL-1β.
Moreover, even though Notch1ICD strongly 
amplified the increase in VCAM1 expression in response 
to the cytokine, BAY pretreatment markedly inhibited this 
phenomenon (Figure 5A, 5B). Finally, BAY also decreased 
the induction of Jagged1 under all experimental conditions 
tested (Figure 5B). 
These results confirm that endothelial Notch1 
activation enhances VCAM1 expression by a mechanism 
involving NF-kB activation.
Jagged1 and Notch1 are upregulated in rat liver 
vessels with low-grade chronic inflammation
We investigated the possible deregulation of 
Jagged1 and Notch1 in inflamed endothelial cells in vivo, 
in an animal model of low-grade chronic inflammation. 
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Figure 3: The silencing of Notch1 and Jagged1 impairs IL-1β-induced VCAM1 upregulation in human aortic 
endothelial cells (HAECs). (A., left) HAECs were transiently transfected with either small interfering oligo RNAs (siRNAs) targeting 
Jagged1 (375 nM) or non-targeting control siRNAs (Scramble siRNA) and, 48 h later, they were treated with IL-1β (10 ng/ml) for 6 h 
or left untreated. The cells were then harvested and analyzed by flow cytometry. Representative histogram showing overlays of VCAM1 
expression analyzed by flow cytometry: Scramble siRNA (gray solid curve), Jagged1 siRNA (dotted line), IL-1β + Scramble siRNA (gray 
line) and IL-1β + Jagged1 siRNA (black line). (A., right) The histogram depicts the quantification of VCAM1 expression in IL-1β-treated 
cells analyzed by flow cytometry and expressed as a mean fluorescence intensity (MFI) in arbitrary values. Mean±SD. B. Representative 
western blot showing levels of Jagged1 and Notch1 intracellular domain (Notch1ICD) in HAECs treated as in A. β-actin is the loading 
control. (C., left) HAECs were transiently transfected with either a siRNA targeting Notch1 (375 nM) or non-targeting control siRNAs 
(Scramble siRNA) and, 48 h later, they were treated with IL-1β (10 ng/ml) or left untreated for 6 h, harvested and analyzed by flow 
cytometry. A representative histogram showing overlays of VCAM1 expression analyzed by flow cytometry: Scramble siRNA (gray solid 
curve), Notch1 siRNA (dotted line), IL-1β + Scramble siRNA (gray line) and IL-1β + Notch1 siRNA (black line). (C., right) The histogram 
depicts the quantification of VCAM1 expression in IL-1β-treated cells analyzed by flow cytometry and expressed as a mean fluorescence 
intensity (MFI) in arbitrary values. Mean±SD. D. Representative western blot showing levels of Jagged1 and Notch1 intracellular domain 
(Notch1ICD) in HAECs treated as in C. β-actin is the loading control. (E., left) HAECs were transiently cotransfected with siRNAs 
targeting either Jagged1 (125 nM) or Notch1 (250 nM), or with non-targeting control siRNAs (Scramble siRNA) and, 48 h later, they 
were treated with IL-1β (10 ng/ml) for 6 h or left untreated. They were then harvested and analyzed by flow cytometry. A representative 
histogram showing overlays of VCAM1 expression analyzed by flow cytometry: Scramble siRNA (gray solid curve), Jagged1 siRNA + 
Notch1 siRNA (dotted line), IL-1β + Scramble siRNA (gray line) and IL-1β + Jagged1 siRNA + Notch1 siRNA (black line). (E., right) 
The histogram depicts the quantification of VCAM1 expression, analyzed by flow cytometry, in IL-1β-treated cells and expressed as a 
mean fluorescence intensity (MFI), in arbitrary values. Mean±SD. F. Representative western blot showing levels of Jagged1 and Notch1 
intracellular domain (Notch1ICD) in HAECs treated as in E. β-actin expression was used as the loading control. All experiments were 
performed in triplicate and repeated independently at least 3 times. *P < 0.05, **P < 0.01, ***P < 0.001, t-test
Oncotarget43222www.impactjournals.com/oncotarget
Figure 4: Forced expression of Notch1ICD increases VCAM1 expression in human aortic endothelial cells (HAECs). 
HAECs were co-nucleofected with a plasmid encoding the Notch1 intracellular domain (Notch1ICD) and a plasmid encoding the green 
fluorescent protein (GFP) (3:1 molar proportion) and, 48 h later, they were treated with IL-1β (10 ng/ml) for 6 h or left untreated. They were 
then harvested and analyzed by flow cytometry. An empty vector (EV) was used as a control. (A., left) Representative histogram showing 
overlays of VCAM1 expression analyzed by flow cytometry: Empty Vector (EV) (gray solid curve), Notch1ICD (dotted line), Empty 
Vector + IL-1β (gray line) and Notch1ICD + IL-1β (black line). (A., right) The histogram depicts the quantification of VCAM1 expression, 
analyzed by flow cytometry and expressed as a mean fluorescence intensity (MFI) in arbitrary values. Mean±SD. B. Representative western 
blot showing levels of Jagged1, Notch1 intracellular domain (Notch1ICD) and VCAM1 in HAECs treated as in A. β-actin is the loading 
control. **P < 0.01, ***P < 0.001, ANOVA (Bonferroni correction)
Figure 5: Notch1ICD-mediated VCAM1 induction is partly counteracted by NF-kB inhibition in human umbilical 
vein endothelial cells (HUVECs). HUVECs were transduced with either a retroviral vector co-expressing a flag-tagged murine 
Notch1ICD (Notch1ICD*) and the enhanced green fluorescent protein (eGFP) or an eGFP vector (EV*) as a control. After 48 h from 
infection, cells were subjected to pretreatment with the NF-kB inhibitor BAY 11-7082 (20 µM) for 1 h or with vehicle (DMSO) and they 
were then treated with IL-1β for 1 h or left untreated. A. Levels of VCAM1 mRNA were quantified by the 2(-∆∆Ct) method (see Materials 
and Methods section) after normalization with respect to β-actin, and expressed as a fold-change relative to EV*-vehicle-treated cells (1 
arbitrary unit). Mean±SD. B. Representative western blot showing levels of intracellular domain (Notch1ICD), Jagged1 and VCAM1 in 
HUVECs treated as in A. α-tubulin is the loading control. The experiments were performed independently and repeated at least twice. **P 
< 0.01, ***P < 0.001, ANOVA (Bonferroni correction). C. Proposed model of Notch1-dependent induction of endothelial VCAM1. In 
endothelial cells, IL-1β reduces the transcription of the Notch4 gene in an NF-kB-dependent manner, leading to downregulation of both 
the active Notch4ICD form and expression of the Notch4 target gene Hes1. Both these both phenomena are responsible, at least in part, 
for the upregulation of VCAM1 in the endothelium. Concomitantly, IL-1β induces VCAM1 expression in an NF-kB-dependent manner. 
In parallel, IL-1β decreases Notch1 transcript levels and upregulates expression of the Notch ligand Jagged1 via a mechanism involving 
NF-kB. Jagged1 binds to Notch1, leading to the cleavage of the receptor and the sustained formation of the activated form Notch1ICD, in 
turn favoring Jagged1 expression. At the same time, Notch1ICD amplifies the NF-kB-dependent VCAM1 expression induced by IL-1β. 
Possibly due to Notch1-inducing VCAM1 upregulation in the absence of IL-1β, the activation of Notch1 also decreases Notch4 and Hes1 
expression.
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We used the high-fat diet (HFD)-rat model, in which the 
histological features of the liver resemble those of human 
non-alcoholic fatty liver disease (NAFLD), as previously 
demonstrated by our group [36]. NAFLD is a common, 
chronic inflammatory liver disease associated with 
obesity  and characterized by a pattern of steatosis 
associated with low-grade CD163-positive inflammation. 
HFD rats have recently been reported to have high serum 
TNF-α levels [37] and to display positive hepatic staining 
for IL-1β [38], which was absent in normal control 
animals. Consistent with these observations, IL-1β mRNA 
levels in the livers of HFD rats were 70% higher than 
those in controls (Figure 6A). Serum TNF-α levels were 
also considerably higher in HFD rats [37] (Figure 6B). 
Immunohistochemical analysis showed that Jagged1 
was expressed by the CD31-positive cells lining the liver 
sinusoids and a few hepatocytes in HFD rats, but not in 
control rats (Figure 6C). Staining for nuclear Notch1ICD 
with an anti-Val1744 antibody recognizing only the 
cleaved form of the receptor [11] showed this protein to 
be present in hepatocytes, as previously reported [39], and 
in the liver endothelial cells of HFD rats, whereas it was 
almost undetectable in controls (Figure 6D).
These results are consistent with the notion that low-
grade chronic inflammation of the liver is associated with 
increases in Jagged1 expression and Notch1 activation in 
endothelial cells. 
DISCUSSION
Our results build on previous reports concerning the 
role of Notch signaling in an endothelial inflammatory 
context. They reveal, for the first time, that Notch1 
activation in endothelial cells mimics the effects of IL-
1β on adhesion molecules and on other Notch signaling 
components. Indeed, we found that (i) the active form 
Notch1ICD was sufficient to induce VCAM1 and Jagged1 
expression in the absence of IL-1β, this induction being 
markedly amplified by the presence of this cytokine, partly 
through NF-kB, with this active form also enhancing the 
induction of expression induced by IL-1β, and (ii) Notch1 
knockdown inhibited this phenomenon. 
Consistent with these findings, Notch1 remained 
activated in the early phase of IL-1β treatment, whereas 
Notch4 did not, despite the decrease in Notch1 mRNA and 
full-length precursor protein levels induced by IL-1β. This 
appears to be due, in part, to the IL-1β-dependent increase 
in Jagged1 levels [27, 40-42], because Jagged1 silencing 
decreased Notch1 activation and was associated with a 
decrease in VCAM1 expression. 
These results suggest that there is a cell-autonomous 
positive feedback loop between Notch1 and Jagged1 
during the early stages of inflammation, sustaining Notch1 
signaling in endothelial cells and contributing to the 
effects of IL-1β on VCAM1 expression. In later phases 
of the inflammatory response, Notch1 may be required for 
the sustained induction of Jagged1 [27, 43, 44]. 
Despite the decrease in Notch4 signaling caused by 
IL-1β in inflamed endothelium, the decrease in VCAM1 
levels following pretreatment with the γ-secretase inhibitor 
DAPT, a non-selective inhibitor of Notch receptor 
activation, confirmed that Notch activation facilitated the 
endothelial inflammatory phenotype. 
Crosstalk between Notch1 signaling and NF-kB in 
endothelial cells
Our observation that the NF-kB inhibitor BAY 
markedly decreased Notch1ICD and Jagged1 levels in 
cells treated with IL-1β suggests that, in this context, the 
Notch1-Jagged1 positive feedback loop involves Notch1 
signaling through NF-kB. Our results are consistent with 
previous reports that activated NF-kB induces Jagged1, 
which then can trigger Notch signaling transcriptional 
activity, in endothelial cells [27]. By contrast, the 
pretreatment of Notch1ICD cells with BAY only partially 
inhibited the enhancement of both VCAM1 and Jagged1 
expression in the presence or absence of IL-1β. This 
indicates that high levels of Notch1ICD in endothelial 
cells may be involved in NF-kB-independent signaling.
Several mechanisms may underlie the observed 
phenomenon involving NF-kB and Notch1 [5, 43, 45], 
including the occupancy of nearby chromatin sites by NF-
kB and Notch1ICD/RBP-jK [46, 47] and the presence of 
an RBP-jK binding site nested within an NF-kB binding 
site [48]. 
Consistent with these findings, the NF-kB and 
Notch1 signaling pathways cooperate in the stimulation 
of Jagged1 expression in macrophages, but can also act 
independently [43]. However, in light of our results and 
recent reports on the participation of these transcriptional 
regulators in super-enhancers [34, 49], further 
investigations of the chromatin crosstalk between Notch1 
and Jagged1 in the inflamed endothelium are required.
Notch1 regulates the expression of Notch 
components in endothelial cells
Like IL-1β, Notch1ICD modulates other Notch 
signaling components, decreasing Notch4 and Hes1 levels, 
whereas Notch1 knockdown increases the levels of these 
components. The opposite is true for Hey1, suggesting that 
Notch4 signals through Hes1 in endothelial cells, contrary 
to reports for other systems [50]. Previous data have 
shown that the silencing of Notch4, unlike that of Notch1, 
does not modulate the transcription of genes encoding 
other Notch paralogs under the same experimental 
conditions [26, 28] . 
It is not possible to determine whether Hey1 is 
responsible for repressing Notch4 expression from our 
data. However, TNFα-mediated Hey1 induction has been 
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Figure 6: Jagged1 and Notch1 are upregulated in the liver vessels of rats with low-grade chronic inflammation. 
Rats were fed ad libitum with either a high-fat diet (HFD) or standard chow (SD) (control rats) and were analyzed after 3 months. 
A. Representative semi-quantitative RT-PCR for IL-1β mRNA, on total RNA from the livers of SD- or HFD-fed rats. Following the 
preliminary setting up of PCR conditions, each sample was analyzed during the linear phase of amplification and PCR products were 
visualized under UV illumination with gel red (Biotium Inc., Hayward, CA), after electrophoresis in a 1.5% agarose gel. Primer sequences 
are listed in Table 1. HPRT was used as the housekeeping gene. B. Quantification by an enzyme-linked immunosorbent assay (ELISA) 
for TNFα in the serum of SD- and HFD-fed rats. C. Immunohistochemical staining showing CD31 (top) and Jagged1 (bottom) expression 
on endothelial cells from serial sections of liver samples from SD- and HFD-fed rats. Positive cells are indicated by brown staining. The 
arrows indicate the endothelial cells lining the blood vessels. 600x magnification. D. Double-labeling immunofluorescence analysis of 
Notch1ICD (green), with an anti-Val1744 antibody that detects only the cleaved form of the receptor, and CD31 (red) on serial sections 
of liver from SD- and HFD-fed rats. Nuclei are counterstained with DRAQ5. Blue arrows indicate Notch1ICD-negative nuclei (SD rats), 
yellow arrows indicate Notch1ICD-positive nuclei and pink arrows indicate Notch1ICD-positive cytoplasmic staining (HFD rats). A white 
arrow indicates a Notch1ICD-positive liver parenchymal nucleus. Top panels, 600 x magnification; lower panels are a higher magnification 
(2400 x magnification) of the squared area in the top panels. A representative set of images is shown. **P < 0.01 t-test.
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shown to result from Notch2ICD overexpression [28]. 
As activated Notch1 strongly induces Notch2 expression 
(our data and [28, 30]), the upregulation of Hey1 may 
be dependent on Notch2, which does not regulate the 
expression of adhesion molecules ([28, 30] and our 
unpublished observations). 
An example of opposite patterns of regulation by 
IL-1β has been reported for two Notch paralogs in the 
vascular bed, with this cytokine inducing Notch1 and 
Hey1 and downregulating Notch3 and Hes1 in vascular 
smooth muscle cells (VSMCs) [23]. 
We also showed that the expression of Notch1ICD 
and Jagged1 was upregulated in the liver endothelial cells 
of rats with hepatic chronic inflammation (i.e., NAFLD), 
as previously reported for hepatocytes [39]. This result 
is consistent with the notion that endothelial Notch1 is 
activated by inflammatory cytokines, such as IL-1β and 
TNFα, in vivo and suggests that Notch1 may play a role in 
chronic endothelial inflammation. 
CONCLUSIONS
In summary, we describe a novel pro-inflammatory 
role for endothelial Notch1, opposing that of Notch4 
(Figure 5C), and suggest that there may be an endothelial 
Notch1-Jagged1 cell-autonomous circuit supporting the 
endothelial inflammatory phenotype and involving NF-kB. 
Notch1 has already been implicated in endothelial 
functions and in vascular biology in general, but our 
results highlight, for the first time, the involvement 
of this Notch paralog in the regulation of endothelial 
inflammatory adhesion molecules. The mechanisms 
underlying such paralog-specific effects and their possible 
pathophysiological relevance require further investigation, 
to improve the precision of Notch signal modulation in 
inflamed endothelia [50]. 
MATERIALS AND METHODS
Cell culture and reagents
Primary human arterial endothelial cells (HAECs) 
and primary human umbilical vein endothelial cells 
(HUVECs) were purchased from Lonza Group Ltd. (Basel, 
Switzerland), cultured in EGM-2 complete medium 
(Lonza Group Ltd, Basel, Switzerland), and used between 
passages 4 and 7. Confluent cell monolayers were treated 
with IL-1β (Peprotech, Rocky Hill, NJ) 10 ng/ml in EBM-
2 (Lonza Group Ltd, Basel, Switzerland) supplemented 
with 0.5% FCS (Hyclone, Logan, UT); DAPT and BAY 
11-7082 (both from Sigma Chemical Co., St Louis, MO) 
were dissolved in DMSO and used at concentrations of 5 
μM or 10 μM (DAPT) and 20 μM (BAY 11-7082) for the 
indicated times.
Transient RNA interference and transfection with 
plasmids
Endothelial cells were transfected with siRNAs 
against Jagged1 and Notch1 (Sasi_Hs01_00100442 and 
Sasi_Hs01_00052328, respectively; Sigma Chemical 
Co., St Louis, MO), in the presence of Oligofectamine 
(Invitrogen Corp., Carlsbad, CA) in Opti-MEM, at a 
final concentration of 375 nM, following the preliminary 
setup recommended by the manufacturer. For double-
knockdown experiments, cells were cotransfected with 
125 nM and 250 nM siRNA for Jagged1 and Notch1, 
respectively, this combination having been found to yield 
the best simultaneous silencing for both molecules (data 
not shown). 
A non-targeting FITC-conjugated siRNA (Scramble) 
was used as a control for silencing (Sigma Chemical Co., 
St Louis, MO). For overexpression studies, pCMV-GFP 
was used in a molar proportion of 1:3 with a pcDNA3 
vector encoding human Notch1ICD or the empty vector 
(a gift from M. Bocchetta, Loyola University of Chicago 
[10]). Nucleofection was performed with an Amaxa 
Nucleofector (Lonza Group Ltd, Basel, Switzerland), 
with the Amaxa basic nucleofector kit for primary 
endothelial cells (Lonza Group), according to the 
manufacturer’s instructions. Assays were performed 48 h 
after transfection. 
Western blot analysis
Cells were lysed in RIPA buffer supplemented with 
protease inhibitor cocktail (Roche Life Science, Roche 
Diagnostics S.p.A. Monza (MB), Italy), sonicated for 
30 minutes on ice, and the lysate was then centrifuged 
(20,000 x g, 20 min). The protein concentration of samples 
was determined by the BCA method (Pierce, Rockford, 
IL), according to the manufacturer’s instructions. Proteins 
(40 μg) were run on SDS-polyacrylamide gels and blotted 
onto nitrocellulose membranes, which were blocked by 
incubation with 10% non-fat milk at room temperature for 
1 h. The membranes were probed with primary antibodies 
(Jagged1 1:1000, Notch1 (bTAN) 1:1000, Notch2 1:1000 
(DSHB, Iowa City, IA), Notch4 1:1000 (R&D Systems 
Europe, Ltd., Abingdon, UK), VCAM1 1:1000 and 
β-actin 1:20000 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), and an antibody against Notch1ICD cleaved at 
Val1744, recognizing both human and murine Notch1ICD 
(Cell Signaling, Beverly, MA)), by incubation overnight at 
4°C with the appropriate antibody in TBS, 0.05% Tween 
20, 5% milk. The membrane with then incubated with a 
horseradish peroxidase-conjugated secondary antibody 
(Santa Cruz Biotechnology) for 1 h at room temperature, 
and enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) was performed according to kit 
manufacturer’s instructions. 
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Reverse transcriptase-quantitative polymerase 
chain reaction (RT-qPCR)
RNA was extracted with TRIzol reagent 
(Invitrogen), according to the manufacturer’s instructions. 
The RNA was treated with DNase I and used as a template 
for generation of the first-strand cDNA by Super Script 
II Reverse Transcriptase (Invitrogen), according to the 
manufacturer’s instructions. Quantitative PCR assays 
were performed with either the Sybr Green method 
(Figure 1 and Supplementary Figures 1) or TaqMan assays 
(Figures 2 and 5, and Supplementary Figures 3-5; Applied 
Biosystems, Life Technologies, Carlsbad, CA). With the 
Sybr Green method, samples were analyzed in the linear 
phase of amplification, as previously described [23]. The 
primer sequences used to amplify the desired cDNAs are 
detailed in Supplementary Table 1. The PCR templates 
consisted of 250 ng of cDNA or purified standard DNA. 
Amplification was performed with a spectrofluorometric 
thermal cycler (LightCycler 480, Roche Diagnostics, 
Meylan, France). After the initial denaturation step at 95°C 
for 5 min, amplification was performed with 50 cycles of 
denaturation (95°C for 10 s), annealing (60°C for 15 s) 
and extension (72°C for 10 s). For each run, a standard 
curve was generated from purified DNA, ranging from 10 
to 106 copies, and samples were quantified with the C
T
, 
by interpolation from the standard curve to yield a copy 
number for the cDNA corresponding to each gene. Gene 
expression values were normalized by dividing the copy 
number of the target gene by that of the β-actin gene, used 
as a housekeeping gene [23]. 
Quantitative PCR was performed with the following 
TaqMan probes: VCAM1 (Hs01003372_m1), Hey1 
(Hs01114113_m1), Hes1 (Hs00172878_m1), Jagged1 
(Hs01070036_m1), Notch1 (Hs01062014_m1), Notch2 
(Hs01050719_m1), Notch4 (Hs00965882_m1) and β-actin 
(Hs99999903_m1), used as a housekeeping gene (Applied 
Biosystems, Life Technologies, Carlsbad, CA), with an 
Applied Biosystems 7900 system. The fold-change in gene 
expression was calculated by the 2(-∆∆Ct) method [51]. At 
least three independent amplifications were performed for 
each gene, with samples analyzed at least in duplicate.
Fluorescence-activated cell sorting (FACS) 
analysis
For antigen detection by FACS, cell monolayers 
were detached with Versene (Invitrogen Corp., Carlsbad, 
CA), washed and incubated with the primary antibodies 
against VCAM1 (BD Pharmingen, San Jose, CA), ICAM1 
(Invitrogen Corp., Carlsbad, CA) and E-selectin (Upstate 
Biotechnology, Lake Placid, NY), or isotype-matched 
IgG antibodies as negative controls, diluted (1:20) in 
PBS 5% FCS and for 30 minutes on ice. Cy5-conjugated 
anti-mouse secondary IgG (Jackson Immunoresearch 
Laboratories, PA) diluted (1:100) in PBS were incubated 
with the cells for 20 minutes on ice. Acquisition was 
performed on a FACS LSR1 Cytometer (BD Biosciences, 
San Jose, CA) with MacIntosh CellQuest Pro software. 
Retroviral infection
The CMMP-IRES-EGFP retroviral vector 
expressing a flag-tagged murine Notch1ICD and the 
control empty CMMP-IRES-EGFP vector have been 
described elsewhere [33]. Phoenix Ampho cells obtained 
from ATCC were cultured in DMEM supplemented with 
10% FBS and transiently transfected by the calcium 
phosphate method. Supernatants containing viral particles 
were collected after 48 h and used to infect HUVECs 
for 48 h (two rounds of 12 h infection) in the presence 
of 5 μg/ml polybrene (two rounds of infection). The 
HUVECs were then subjected to pretreatment with vehicle 
(DMSO) or DAPT (10 µM) for 16 h and harvested for 
examination. In parallel, infected HUVECs were subjected 
to pretreatment with either BAY 11-7082 (20 µM) or 
vehicle (DMSO) for 1 h, and then treated with 10 ng/ml 
IL-1β or vehicle (DMSO) for 1 h and then harvested for 
examination.
Animal model of non-alcoholic fatty liver disease 
(NAFLD)
Rats were provided with free access to standard 
chow for 5 days and were then randomized (6 rats per 
group) to a standard diet group (SD) and a high-fat 
diet group (HFD). The standard chow was from Harlan 
Laboratories (Harlan Laboratories, Inc., Correzzana 
(MB), Italy) and the high-fat chow was purchased from 
Laboratorio Dottori Piccioni (Gessate (MI), Italy) and 
contained 58% energy from fat, 18% from protein, and 
24% from carbohydrates (5.6 kcal/g), whereas the normal 
chow contained 5% energy derived from fat, 18% from 
proteins, and 77% from carbohydrates (3.3 kcal/g). All 
rats were killed after three months of diet. At the indicated 
time points, livers were excised, weighed and processed 
for immunohistochemical analysis or RNA extraction. 
Blood samples were collected for the determination of 
TNFα levels.
Immunohistochemistry and immunofluorescence
Liver tissues from NAFLD and control animals were 
fixed by incubation in 10% formalin at room temperature 
for 24 h and embedded in paraffin. The specimens were cut 
into 2 µm section, which were deparaffinized, rehydrated 
and blocked. After citrate-based antigen retrieval (pH 6 
and pH 9 for CD31 and Jagged1, respectively), sections 
were incubated with primary antibodies: 1:50 mouse 
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monoclonal anti-CD31 (Novocastra, Newcastle Upon 
Tyne, UK) and 1:50 rabbit monoclonal anti-Jagged1 (Cell 
Signaling, Beverly, MA). The secondary antibody was 
provided by the Labelled Streptavidin Biotin (LSAB) 
kit (Dako Denmark A/S, Glostrup, Denmark). The 
diaminobenzidine (DAB) substrate chromogen kit (Dako 
Denmark A/S, Glostrup, Denmark) was used for detection. 
Nuclei were counterstained with Gill’s hematoxylin. 
Positive reactions, indicated by brown staining, were 
observed with an Eclipse E600 microscope (Nikon 
Instruments, Firenze, Italy) and images were acquired with 
a Nikon Digital Camera DXM1200F and Lucia version 
4.81 software.
Immunofluorescence was analyzed on 2 µm-thick 
sections obtained from formalin-fixed tissue embedded 
in paraffin. Antigen retrieval was performed with EDTA 
(pH 8) (Dako Denmark A/S, Glostrup, Denmark). Sections 
were then incubated with primary antibodies: 1:100 mouse 
monoclonal anti-CD31 (Novocastra, Newcastle Upon 
Tyne, UK) and 1:300 rabbit polyclonal Cleaved Notch-
Val1744 (Cell Signaling, Beverly, MA). The secondary 
antibodies used for staining were: 1:500 Alexa Fluor 
555-conjugated goat anti-mouse and 1:500 Alexa Fluor 
488-conjugated goat anti-rabbit antibodies purchased 
from Applied Biosystems (Life Technologies, Carlsbad, 
CA). Nuclei were counterstained with DRAQ5 (Biostatus, 
Shepshed, UK) for 5 min and, after extensive washing, 
sections were mounted in PBS/glycerol (1:1) and covered 
with a coverslip. Images were acquired with an Olympus 
Fluoview FV1000 confocal microscope equipped with a 
60x (numerical aperture: 1.42) oil objective. Optical single 
sections were acquired with a scanning mode format of 
1024x1024 pixels, and a sampling speed of 20 μs/pixel, 
and 12 bits/pixel image. Fluorochrome signals were 
separated by the acquisition of an automated sequential 
collection of multi-channel images, to reduce spectral 
crosstalk between channels. The pinhole aperture was 1 
Airy unit.
Enzyme-linked immunosorbent assay
Serum TNFα levels were assessed by ELISA 
(Peprotech, Rocky Hill, NJ), according to the kit 
manufacturer’s instructions.
Statistics
Statistical analysis was performed with Student’s 
t-test or ANOVA (with Bonferroni correction for multiple 
testing) for multiple comparisons. A P-value < 0.05 was 
considered significant.
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